Myriamed GmbH

03/09/2026

Advancing human-relevant drug development with engineered 3D tissue models 🚀

Developing new therapeutics remains complex, costly, and time-consuming. A key challenge is generating physiologically relevant data early enough to support decisions on efficacy, safety, candidate selection, and dosing before clinical development.

At myriamed GmbH in Göttingen, Germany, human stem-cell-derived 3D tissue models address this challenge by reproducing relevant aspects of human physiology and disease in vitro. The platforms support early drug discovery, candidate refinement, safety assessment, and dose definition for first-in-human studies.

At the core is myrTissue-Cardio, a bioengineered human cardiac tissue derived from induced pluripotent stem cells (iPS cells). These 3D tissues contract rhythmically and reproduce key functional characteristics of human myocardium, enabling functional drug testing in a human-based system.
Building on this technology, myriamed GmbH combines myrPlates and the myrImager, developed with SYNENTEC.

🧫 myrPlates are 48-well 3D cell and tissue culture plates for the construction and long-term cultivation of engineered tissues. Flexible stretchers support ring-shaped tissue formation under defined mechanical load, while fluorescent markers enable optical tracking of tissue-generated forces.

📸 myrImager is an automated imaging and analysis platform developed for myrPlates. It enables non-invasive, high-precision, high-throughput analysis of cardiac tissue function without direct cell imaging, including longitudinal measurements.

Together, myrPlates + myrImager enable:
• Functional analysis of 3D cardiac tissue
• Reproducible high-throughput screening
• Longitudinal functional measurements
• Human-relevant efficacy and safety assessment
• Reduced reliance on animal testing
• Improved prediction of drug effects before clinical trials

Evaluating drug candidates in human-like functional tissues earlier can help identify promising compounds and potential efficacy or safety liabilities before they reach patients.

Beyond cardiac applications, myriamed also develops advanced 3D models for skeletal muscle and brain research — contributing to more predictive, human-relevant, efficient, and ethical drug development and the advancement of personalized medicine.

📍 myriamed GmbH | Göttingen, Germany
www.myriamed.com | [email protected]
📞 +49 551 2887817 0

myriamed – testing the future of medicine. Today.

30/07/2026

🔬 Bridging the Gap Between Standard Cell Models and Human Physiology 🧬

A major bottleneck in modern drug discovery is the limitation of classical human cell models. Standard 2D cell cultures and basic micro-tissue models often lack true organ physiology and functional maturity—making them an unreliable surrogate for the actual patient.

At myriamed, we are tackling this challenge head-on.

Our wholly human platforms are engineered for the highest degree of functional maturation.

By capturing the complex functional properties characteristic of both health and disease, we enable:
✨ Reliable Translation: Linking engineered organ function with clinical biomarkers to streamline the jump from preclinical stages to clinical trials.
🎯 Mechanism & Dosing Clarity: Performing detailed Mode of Action (MoA) analyses and building rationale dosing strategies for early-stage trials.
🧬 Targeting Human-Specific Biology: Providing a robust alternative when animal models fail—especially for modern therapies targeting specific human proteins, RNA, or DNA.

Ready to bring true human physiology to your drug development pipeline?

👉 Discover our engineered platforms: www.myriamed.com

25/06/2026

Exciting days at the 10th Cardiovascular Bioengineering Symposium in Göttingen!

From 18–20 June 2026, the 10th CVBE brings together leading experts in cardiovascular repair and regeneration at the German Primate Center in Göttingen Deutsches Primatenzentrum GmbH.

The symposium offers inspiring talks, presentations, and discussions on fundamental regenerative mechanisms, cardiovascular disease modelling and repair, as well as emerging cell, gene, tissue, secretome, and nucleotide therapies.

The myriamed GmbH team is excited to be part of this anniversary event and to present our product portfolio — including our high-throughput imaging system, the myrImager.

A big thank you to our partners and friends at SYNENTEC for the successful co-development of the myrImager and the accompanying analysis software. We truly value this collaboration and are proud of what we have achieved together.

We look forward to many more inspiring conversations with pioneers in cardiovascular bioengineering!

13/05/2026

DRUG-SCREENING ON CONTRACTILE TISSUE

The myrImager is a video-optical high-throughput imaging platform designed to work seamlessly with the myriamed 48-well 3D cell/tissue culture plates. Together, they provide an advanced imaging solution for iPSC-derived tissue models used in research and drug screening aligned with ICH hERG testing guidelines.

The myrImager is a high-throughput drug screening platform to image pluripotent stem cells-based tissues like heart muscle (cardiomycytes), skeletal muscle and connective tissue in myrPlates and performs contraction kinetics (force-time curves) e.g. for funtional IC50/EC50 studies.

28/04/2026

Great to see the energy of the European biotech ecosystem here in Munich 🇩🇪

Yesterday marked the first day of BioVaria 2026, where our CEO Arne Östlind is representing myriamed. The event once again brings together innovators, startups, investors, and industry leaders across life sciences – and the exchange so far has been truly inspiring.

From cutting-edge technologies to promising early-stage innovations, day one highlighted the strength of collaboration between academia and industry that continues to drive our field forward.

Today, we’re heading into day two, looking forward to:
🔹 continuing great conversations
🔹 deepening existing connections
🔹 exploring new partnership opportunities

If you’re at BioVaria today, let’s connect!

25/04/2026

Developing new medicines is complex, costly, and time-consuming. At myriamed GmbH, based in Göttingen, Germany, we help drug developers make better decisions earlier — using advanced human stem-cell-derived 3D tissue models that simulate health and disease directly in the dish. myriamed’s engineered tissue platforms are designed to support early drug discovery, candidate refinement, safety assessment, and dose definition for first-in-human studies.

At the core of this approach is myrTissue-Cardio: bioengineered human cardiac tissue derived from iPS cells. These 3D heart muscle models beat rhythmically, mimic key features of human myocardium, and enable highly relevant functional testing of drug candidates in a human-based system.

Now, myriamed takes this technology one step further with the powerful combination of myrPlates and myrImager.

🧫 myrPlates are 48-well 3D cell and tissue culture plates designed for the construction and long-term culture of engineered tissues. Each well contains flexible stretchers that support tissue formation in a ring format under defined mechanical load. The stretchers include fluorescent markers for optical tracing of mechanical forces generated by the tissue.

📸 myrImager is a state-of-the-art automated imaging and analysis platform developed for use with myrPlates. It enables non-invasive, high-precision, high-throughput analysis of cardiac tissue function — without direct cell imaging — and is designed for laboratories in research, biotechnology, and pharmaceuticals.

Together, myrPlates + myrImager create a comprehensive solution for using engineered human tissues in drug development:

✅ Functional analysis of 3D cardiac tissue
✅ Reproducible high-throughput screening
✅ Longitudinal measurements over time
✅ Human-relevant insights into efficacy and safety
✅ Reduced reliance on animal testing
✅ Better prediction of drug effects before clinical trials

This combination makes it possible to evaluate drug candidates on human-like tissue responses earlier, faster, and with greater physiological relevance — helping researchers identify promising compounds and detect potential risks before they reach patients.

Beyond cardiac tissue, myriamed also develops advanced 3D models for skeletal muscle and brain research, supporting a broader vision: accelerating personalized medicine and making drug development more predictive, ethical, and efficient.

📍 myriamed GmbH
Rudolf-Wissell-Straße 28a
37079 Göttingen, Germany
📞 +49 551 2887817 0
www.myriamed.com
[email protected]

➡️ myriamed – testing the future of medicine. Today. 🧪✨

21/04/2026

myriamed GmbH is excited to be heading to BioVaria in Munich on April 27–28, 2026!

Our CEO, Arne Östlind , will be on-site and looking forward to connecting with innovators, partners, and investors across the life sciences ecosystem.

At myriamed GmbH , we’re passionate about accelerating drug development and supporting breakthrough therapies from concept to clinic.

Events like BioVaria are a fantastic opportunity to exchange ideas, explore collaborations, and help shape the future of healthcare.

If you’re attending, let’s connect! 🤝

Feel free to reach out and schedule a meeting.

15/04/2026

15/04/2026

When tissue models start to contract: a shift toward functional relevance in drug discovery !

myriamed GmbH´s 3D organoids cultured on MyrPlates illustrate how advanced model systems are moving beyond structural representation toward measurable functionality. The coordinated contractions observed in these organoids are not merely visually compelling—they reflect tissue-level organization, intercellular coupling, and emergent physiological behavior that more closely approximates in vivo conditions than traditional 2D cultures.

🔬 Such functional phenotypes provide biologically meaningful readouts. Contractility, for example, can serve as a quantitative endpoint for pharmacological profiling, toxicity assessment, and disease modeling. This enables a more nuanced evaluation of compound effects early in the development process.

Within this integrated setup, the MyrImager adds an important analytical dimension. By enabling high-resolution, time-resolved imaging of organoid behavior directly on the MyrPlates, it facilitates the quantitative capture of dynamic phenotypes such as contraction patterns, frequency, and amplitude.

📊 This allows functional readouts to be systematically recorded, compared, and incorporated into data-driven workflows.

In this context, myriamed GmbH ’s platforms and services support the generation of standardized, scalable 3D organoid models combined with compatible imaging and assay technologies. By increasing physiological relevance while maintaining experimental control, these systems can enhance the predictive power of preclinical testing and contribute to more informed decision-making in lead identification and optimization.

As the field continues to prioritize translational validity, integrating functional 3D models with quantitative imaging may help reduce late-stage attrition and improve overall R&D efficiency.

How are you integrating functional readouts like contractility into your preclinical models?